King Faisal Specialist Hospital, Riyadh – United Arab Emirates
About Dr. Abdullah Alamer
Dr. Abdullah Alamer is a Consultant in Adult Hematology specialising in Lymphoma and Multiple Myeloma, with a focus on plasma cell disorders, stem cell transplantation, and cellular therapy for international patients seeking expert Lymphoma / Myeloma Consultant care in Riyadh, Saudi Arabia. He is an active member of the Saudi Myeloma Working Group and contributes to national clinical guideline development for relapsed/refractory multiple myeloma.
- Consultant Hematologist specialising in Lymphoma, Multiple Myeloma and plasma cell disorders
- Co-author of the 2025 Saudi Myeloma Working Group Guidelines on Relapsed/Refractory Multiple Myeloma
- Recent lead author on a 2025 peer-reviewed review of rare plasma cell disorders (IgD, IgE, IgM MM, PCL)
- Active in CAR-T cell therapy research and point-of-care cellular therapy programmes
- Experienced in treating international patients from GCC, Africa and South Asia
Qualifications & Credentials
Medical Degrees
- MBBS — Bachelor of Medicine and Bachelor of Surgery
- Internal Medicine Residency — Saudi Arabia
Fellowships & Special Training
- Fellowship in Adult Hematology
- Fellowship in Stem Cell Transplantation and Cellular Therapy
- Advanced training in Multiple Myeloma and Plasma Cell Disorders
Certifications & Accreditations
- Saudi Commission for Health Specialties (SCFHS) — Registered Consultant
- Saudi Myeloma Working Group — Active Member
Areas of Expertise
Major Conditions Treated
- Multiple Myeloma (Newly Diagnosed and Relapsed/Refractory)
- Hodgkin Lymphoma
- Non-Hodgkin Lymphoma (including Diffuse Large B-Cell Lymphoma)
- Plasma Cell Leukaemia
- Waldenström Macroglobulinaemia
- Monoclonal Gammopathy of Undetermined Significance (MGUS)
- Amyloidosis (AL)
- Heavy Chain Disease
- Rare Plasma Cell Disorders (IgD, IgE, IgM, Non-Secretory Myeloma)
Sub-specialties
- Multiple Myeloma Management: Newly diagnosed and relapsed/refractory myeloma treatment using proteasome inhibitors, immunomodulatory agents, and monoclonal antibodies — a trusted lymphoma and myeloma specialist in Riyadh for international patients.
- Stem Cell Transplantation: Autologous and allogeneic haematopoietic stem cell transplantation for lymphoma and myeloma patients as part of KFSHRC's tertiary transplant programme.
- Cellular Therapy & CAR-T: CD19-directed CAR-T cell therapy for relapsed/refractory B-cell lymphomas; active in Middle East regional point-of-care CAR-T research.
Advanced Procedures & Treatments
- Autologous Stem Cell Transplantation (Auto-HSCT)
- Allogeneic Stem Cell Transplantation (Allo-HSCT)
- CAR-T Cell Therapy (Axi-Cel and point-of-care platforms)
- Bispecific Antibody Therapy
- Proteasome Inhibitor Regimens (Bortezomib, Carfilzomib)
- Immunomodulatory Drug Therapy (Lenalidomide, Pomalidomide)
- Monoclonal Antibody Therapy (Daratumumab, Elotuzumab)
- Bone Marrow Biopsy and Aspiration
Professional Experience
Current Affiliation
- King Faisal Specialist Hospital & Research Centre (KFSHRC), Riyadh — Consultant, Lymphoma / Myeloma, Department of Hematology, Stem Cell Transplant and Cellular Therapy, Oncology Center (Present)
Academic & Research Roles
- Member — Saudi Myeloma Working Group (National Guideline Development)
- Contributor — KFSHRC Multidisciplinary Lymphoma / Myeloma Tumour Board
Key Achievements
- Co-author of the Saudi Myeloma Working Group Guidelines on Relapsed/Refractory Multiple Myeloma (2025)
- Lead author of a peer-reviewed review on rare plasma cell disorders published 2025
- Contributed to Saudi Arabia's first real-world Axi-Cel CAR-T series for refractory B-cell lymphoma
- Active contributor to the KFSHRC CAR-T cell therapy programme — the first CAR-T programme in the region
Awards & Recognitions
National & International Awards
- Information not publicly available.
Professional Memberships
- Saudi Myeloma Working Group
- Saudi Society of Hematology
- American Society of Hematology (ASH)
Research & Publications
Published Papers (Selected)
- Alhejazi A, Alotaibi G, Al Saleh A, ..., Alamer A, et al. "Guidelines on Management of Multiple Myeloma in the Relapsed/Refractory Setting: The Saudi Myeloma Working Group Guideline." Clinical Lymphoma Myeloma and Leukemia. 2025;25(10):e756-e765. DOI: 10.1016/j.clml.2025.05.005.
- Alamer A, Alhayli S, et al. "Uncommon Entities, Uncommon Challenges: A Review of Rare Plasma Cell Disorders." MDPI Journal. 2025 (Aug).
- Alotaibi G, Al Saleh A, Alhejazi A, ..., Alamer A, et al. "Definition, diagnosis, risk stratification and management of newly diagnosed multiple myeloma: The Saudi Myeloma Working Group Guidelines." Clinical Lymphoma Myeloma and Leukemia. 2025. DOI: 10.1016/j.clml.2025.06.005.
- Alsuhaibani K, ..., Alamer A, et al. "Non-Western Real-World Experience of Axi-Cel CAR-T in Refractory/Relapsed B-Cell Lymphoma from a Tertiary Center in Saudi Arabia." Blood. 2024;144(Suppl 1):7824.
Ongoing Research & Clinical Interests
- Relapsed/refractory multiple myeloma treatment optimisation
- CAR-T cell therapy in B-cell malignancies
- Rare plasma cell disorders (IgD, IgE, IgM myeloma)
- Point-of-care cellular therapy manufacturing in the Middle East
Estimated Treatment Costs
| Procedure / Consultation | Estimated Cost (INR) | Estimated Cost (USD) |
|---|---|---|
| Hematology / Oncology Consultation | ₹2,000 – ₹5,000 | $25 – $60 |
| Chemotherapy (per cycle, regimen-dependent) | ₹25,000 – ₹2,00,000 | $300 – $2,400 |
| Autologous Stem Cell Transplant | ₹15,00,000 – ₹25,00,000 | $18,000 – $30,000 |
| Allogeneic Stem Cell Transplant | ₹25,00,000 – ₹45,00,000 | $30,000 – $54,000 |
| CAR-T Cell Therapy | ₹1,25,00,000 – ₹3,50,00,000 | $150,000 – $420,000 |
| Bone Marrow Biopsy | ₹10,000 – ₹25,000 | $120 – $300 |
*Indicative estimates only. Actual costs subject to hospital pricing, case complexity, and insurance. Contact Cancer Rounds for a personalised quote.
Frequently Asked Questions
1. What advanced technologies does Dr. Abdullah Alamer use in Lymphoma / Myeloma treatment?
Dr. Abdullah Alamer employs evidence-based precision therapies including CAR-T cell therapy (Axi-Cel), autologous and allogeneic stem cell transplantation, proteasome inhibitors, immunomodulatory agents (lenalidomide, pomalidomide), and monoclonal antibodies (daratumumab). He contributes to point-of-care CAR-T manufacturing research. Virtual consultations are available for international patients — contact Cancer Rounds for a detailed technology overview.
2. What conditions does Dr. Abdullah Alamer specialize in treating?
Dr. Abdullah Alamer specialises in multiple myeloma (newly diagnosed and relapsed/refractory), Hodgkin and non-Hodgkin lymphoma including diffuse large B-cell lymphoma, plasma cell leukaemia, Waldenström macroglobulinaemia, MGUS, amyloidosis, and rare plasma cell disorders. International patients seek his expertise as a lymphoma and myeloma specialist in Riyadh, Saudi Arabia.
3. How do I book an appointment with Dr. Abdullah Alamer?
Appointments with Dr. Abdullah Alamer can be booked directly through the Cancer Rounds website or by contacting their international patient department for priority scheduling.
4. Can international patients receive treatment from Dr. Abdullah Alamer?
Yes. Cancer Rounds provides full assistance for international patients seeking treatment from Dr. Abdullah Alamer, including medical visa invitation letters, airport transfers, and local accommodation coordination.
5. What support is available for international patients?
International patients benefit from a dedicated concierge service provided by Cancer Rounds, including language interpretation, financial counselling, and pre-travel virtual consultations to review medical records before arrival.
6. Does Dr. Abdullah Alamer offer second opinions for Lymphoma / Myeloma cases?
Yes. Second opinion consultations for Lymphoma / Myeloma can be arranged via Cancer Rounds for patients who wish to review their diagnosis or treatment plan with an expert hematologist in Riyadh, Saudi Arabia.
